Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy
Background: To evaluate the effect of reversion to YMDD wild‐type on emergence of adefovir (ADV)‐resistant mutation and antiviral activity of ADV in lamivudine (LAM)‐ resistant patients. Methods: We determined YMDD mutations and ADV‐resistant mutations before and every 3 months during ADV monother...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2009-01, Vol.24 (1), p.49-54 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 54 |
|---|---|
| container_issue | 1 |
| container_start_page | 49 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 24 |
| creator | Kwon, Hyeok Choon Cheong, Jae Youn Cho, Sung Won Choi, Jae Myoung Hong, Sun Pyo Kim, Soo-Ok Yoo, Wang Don |
| description | Background: To evaluate the effect of reversion to YMDD wild‐type on emergence of adefovir (ADV)‐resistant mutation and antiviral activity of ADV in lamivudine (LAM)‐ resistant patients.
Methods: We determined YMDD mutations and ADV‐resistant mutations before and every 3 months during ADV monotherapy in 33 LAM‐resistant patients using the restriction fragment mass polymorphism (RFMP) method.
Results: Reversion to pure YMDD wild‐type hepatitis B virus (HBV) occurred in 6% (2/33), 9% (3/33), 20% (4/20) and 35% (6/17) of patients after 12, 24, 36 and 48 weeks, respectively. Five (29%) patients were found to have pure YMDD mutants at 48 weeks of therapy. Among 33 patients, 4 (12%) patients developed ADV‐resistant mutations at 48 weeks of therapy. Adefovir‐resistant mutants emerged in all patients after reversion to YMDD wild‐type HBV. The mean serum HBV reductions, evaluated at 24 weeks of therapy, were not different between patients with and without reversion to YMDD wild‐type HBV (−3.1 log10 copies/mL vs−3.4 log10 copies/mL, P > 0.05).
Conclusions: ADV‐resistant mutations emerged after reversion to YMDD wild‐type in LAM‐resistant patients who received ADV monotherapy. Thus, ADV add‐on therapy may be necessary to reduce the incidence of developing ADV resistance in patients with LAM resistance. |
| doi_str_mv | 10.1111/j.1440-1746.2008.05570.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66891079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66891079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4660-4478946581009e22c67a23d483f79e1dde374638fc04470c07649638ecc85ad63</originalsourceid><addsrcrecordid>eNqNkU2P0zAQhiMEYsvCX0C-wC1hHDv-OHBA26XLaoE9gBAnyziTxSUfxU5K-xP41zi0KtzAl7Hk550Z68kyQqGg6bxYF5RzyKnkoigBVAFVJaHY3csWp4f72QIUrXLNqD7LHsW4BgAOsnqYnVFNtWC6WmQ_LzsMd9g7JENDbI3NsPUhDxh9HG0_km6aSyS2GTGQgFsM0Q89GQfy-e1ySX74ts7H_QaJ70lrO7-dat_jXx02dvQ4twjo0G99f3eaQ7qhH8avGOxm_zh70Ng24pNjPc8-vr78cHGV37xfvbl4dZM7LgTknEuluagUBdBYlk5IW7KaK9ZIjbSukaXPM9U4SCg4kIKnvyp0TlW2Fuw8e37ouwnD9wnjaDofHbat7XGYohFCaQpS_xMsgaVdgCdQHUAXhhgDNmYTfGfD3lAwsy-zNrMWM2sxsy_z25fZpejT44zpS4f1n-BRUAKeHQEbnW2bYHvn44krKVBVUUjcywOXfOD-vxcw16ur-Zby-SGfpOHulLfhmxGSycp8ercy18tbekslM4z9AkykwXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20347804</pqid></control><display><type>article</type><title>Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Kwon, Hyeok Choon ; Cheong, Jae Youn ; Cho, Sung Won ; Choi, Jae Myoung ; Hong, Sun Pyo ; Kim, Soo-Ok ; Yoo, Wang Don</creator><creatorcontrib>Kwon, Hyeok Choon ; Cheong, Jae Youn ; Cho, Sung Won ; Choi, Jae Myoung ; Hong, Sun Pyo ; Kim, Soo-Ok ; Yoo, Wang Don</creatorcontrib><description>Background: To evaluate the effect of reversion to YMDD wild‐type on emergence of adefovir (ADV)‐resistant mutation and antiviral activity of ADV in lamivudine (LAM)‐ resistant patients.
Methods: We determined YMDD mutations and ADV‐resistant mutations before and every 3 months during ADV monotherapy in 33 LAM‐resistant patients using the restriction fragment mass polymorphism (RFMP) method.
Results: Reversion to pure YMDD wild‐type hepatitis B virus (HBV) occurred in 6% (2/33), 9% (3/33), 20% (4/20) and 35% (6/17) of patients after 12, 24, 36 and 48 weeks, respectively. Five (29%) patients were found to have pure YMDD mutants at 48 weeks of therapy. Among 33 patients, 4 (12%) patients developed ADV‐resistant mutations at 48 weeks of therapy. Adefovir‐resistant mutants emerged in all patients after reversion to YMDD wild‐type HBV. The mean serum HBV reductions, evaluated at 24 weeks of therapy, were not different between patients with and without reversion to YMDD wild‐type HBV (−3.1 log10 copies/mL vs−3.4 log10 copies/mL, P > 0.05).
Conclusions: ADV‐resistant mutations emerged after reversion to YMDD wild‐type in LAM‐resistant patients who received ADV monotherapy. Thus, ADV add‐on therapy may be necessary to reduce the incidence of developing ADV resistance in patients with LAM resistance.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/j.1440-1746.2008.05570.x</identifier><identifier>PMID: 19196395</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>adefovir ; Adenine - analogs & derivatives ; Adenine - therapeutic use ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - therapeutic use ; antiviral resistance ; Biological and medical sciences ; DNA, Viral - blood ; Drug Resistance, Multiple, Viral - genetics ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis B - diagnosis ; Hepatitis B - drug therapy ; Hepatitis B virus ; Hepatitis B virus - genetics ; Humans ; Lamivudine - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Mutation ; Organophosphonates - therapeutic use ; Pharmacology. Drug treatments ; Polymorphism, Restriction Fragment Length ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Time Factors ; Treatment Outcome ; Viral Load ; YMDD mutants</subject><ispartof>Journal of gastroenterology and hepatology, 2009-01, Vol.24 (1), p.49-54</ispartof><rights>2008 The Authors. Journal compilation © 2008 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4660-4478946581009e22c67a23d483f79e1dde374638fc04470c07649638ecc85ad63</citedby><cites>FETCH-LOGICAL-c4660-4478946581009e22c67a23d483f79e1dde374638fc04470c07649638ecc85ad63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1440-1746.2008.05570.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1440-1746.2008.05570.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4023,27922,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21018510$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19196395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwon, Hyeok Choon</creatorcontrib><creatorcontrib>Cheong, Jae Youn</creatorcontrib><creatorcontrib>Cho, Sung Won</creatorcontrib><creatorcontrib>Choi, Jae Myoung</creatorcontrib><creatorcontrib>Hong, Sun Pyo</creatorcontrib><creatorcontrib>Kim, Soo-Ok</creatorcontrib><creatorcontrib>Yoo, Wang Don</creatorcontrib><title>Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background: To evaluate the effect of reversion to YMDD wild‐type on emergence of adefovir (ADV)‐resistant mutation and antiviral activity of ADV in lamivudine (LAM)‐ resistant patients.
Methods: We determined YMDD mutations and ADV‐resistant mutations before and every 3 months during ADV monotherapy in 33 LAM‐resistant patients using the restriction fragment mass polymorphism (RFMP) method.
Results: Reversion to pure YMDD wild‐type hepatitis B virus (HBV) occurred in 6% (2/33), 9% (3/33), 20% (4/20) and 35% (6/17) of patients after 12, 24, 36 and 48 weeks, respectively. Five (29%) patients were found to have pure YMDD mutants at 48 weeks of therapy. Among 33 patients, 4 (12%) patients developed ADV‐resistant mutations at 48 weeks of therapy. Adefovir‐resistant mutants emerged in all patients after reversion to YMDD wild‐type HBV. The mean serum HBV reductions, evaluated at 24 weeks of therapy, were not different between patients with and without reversion to YMDD wild‐type HBV (−3.1 log10 copies/mL vs−3.4 log10 copies/mL, P > 0.05).
Conclusions: ADV‐resistant mutations emerged after reversion to YMDD wild‐type in LAM‐resistant patients who received ADV monotherapy. Thus, ADV add‐on therapy may be necessary to reduce the incidence of developing ADV resistance in patients with LAM resistance.</description><subject>adefovir</subject><subject>Adenine - analogs & derivatives</subject><subject>Adenine - therapeutic use</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral resistance</subject><subject>Biological and medical sciences</subject><subject>DNA, Viral - blood</subject><subject>Drug Resistance, Multiple, Viral - genetics</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis B - diagnosis</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - genetics</subject><subject>Humans</subject><subject>Lamivudine - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Organophosphonates - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymorphism, Restriction Fragment Length</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><subject>YMDD mutants</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2P0zAQhiMEYsvCX0C-wC1hHDv-OHBA26XLaoE9gBAnyziTxSUfxU5K-xP41zi0KtzAl7Hk550Z68kyQqGg6bxYF5RzyKnkoigBVAFVJaHY3csWp4f72QIUrXLNqD7LHsW4BgAOsnqYnVFNtWC6WmQ_LzsMd9g7JENDbI3NsPUhDxh9HG0_km6aSyS2GTGQgFsM0Q89GQfy-e1ySX74ts7H_QaJ70lrO7-dat_jXx02dvQ4twjo0G99f3eaQ7qhH8avGOxm_zh70Ng24pNjPc8-vr78cHGV37xfvbl4dZM7LgTknEuluagUBdBYlk5IW7KaK9ZIjbSukaXPM9U4SCg4kIKnvyp0TlW2Fuw8e37ouwnD9wnjaDofHbat7XGYohFCaQpS_xMsgaVdgCdQHUAXhhgDNmYTfGfD3lAwsy-zNrMWM2sxsy_z25fZpejT44zpS4f1n-BRUAKeHQEbnW2bYHvn44krKVBVUUjcywOXfOD-vxcw16ur-Zby-SGfpOHulLfhmxGSycp8ercy18tbekslM4z9AkykwXQ</recordid><startdate>200901</startdate><enddate>200901</enddate><creator>Kwon, Hyeok Choon</creator><creator>Cheong, Jae Youn</creator><creator>Cho, Sung Won</creator><creator>Choi, Jae Myoung</creator><creator>Hong, Sun Pyo</creator><creator>Kim, Soo-Ok</creator><creator>Yoo, Wang Don</creator><general>Blackwell Publishing Asia</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200901</creationdate><title>Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy</title><author>Kwon, Hyeok Choon ; Cheong, Jae Youn ; Cho, Sung Won ; Choi, Jae Myoung ; Hong, Sun Pyo ; Kim, Soo-Ok ; Yoo, Wang Don</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4660-4478946581009e22c67a23d483f79e1dde374638fc04470c07649638ecc85ad63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>adefovir</topic><topic>Adenine - analogs & derivatives</topic><topic>Adenine - therapeutic use</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral resistance</topic><topic>Biological and medical sciences</topic><topic>DNA, Viral - blood</topic><topic>Drug Resistance, Multiple, Viral - genetics</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis B - diagnosis</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - genetics</topic><topic>Humans</topic><topic>Lamivudine - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Organophosphonates - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymorphism, Restriction Fragment Length</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><topic>YMDD mutants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwon, Hyeok Choon</creatorcontrib><creatorcontrib>Cheong, Jae Youn</creatorcontrib><creatorcontrib>Cho, Sung Won</creatorcontrib><creatorcontrib>Choi, Jae Myoung</creatorcontrib><creatorcontrib>Hong, Sun Pyo</creatorcontrib><creatorcontrib>Kim, Soo-Ok</creatorcontrib><creatorcontrib>Yoo, Wang Don</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwon, Hyeok Choon</au><au>Cheong, Jae Youn</au><au>Cho, Sung Won</au><au>Choi, Jae Myoung</au><au>Hong, Sun Pyo</au><au>Kim, Soo-Ok</au><au>Yoo, Wang Don</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2009-01</date><risdate>2009</risdate><volume>24</volume><issue>1</issue><spage>49</spage><epage>54</epage><pages>49-54</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background: To evaluate the effect of reversion to YMDD wild‐type on emergence of adefovir (ADV)‐resistant mutation and antiviral activity of ADV in lamivudine (LAM)‐ resistant patients.
Methods: We determined YMDD mutations and ADV‐resistant mutations before and every 3 months during ADV monotherapy in 33 LAM‐resistant patients using the restriction fragment mass polymorphism (RFMP) method.
Results: Reversion to pure YMDD wild‐type hepatitis B virus (HBV) occurred in 6% (2/33), 9% (3/33), 20% (4/20) and 35% (6/17) of patients after 12, 24, 36 and 48 weeks, respectively. Five (29%) patients were found to have pure YMDD mutants at 48 weeks of therapy. Among 33 patients, 4 (12%) patients developed ADV‐resistant mutations at 48 weeks of therapy. Adefovir‐resistant mutants emerged in all patients after reversion to YMDD wild‐type HBV. The mean serum HBV reductions, evaluated at 24 weeks of therapy, were not different between patients with and without reversion to YMDD wild‐type HBV (−3.1 log10 copies/mL vs−3.4 log10 copies/mL, P > 0.05).
Conclusions: ADV‐resistant mutations emerged after reversion to YMDD wild‐type in LAM‐resistant patients who received ADV monotherapy. Thus, ADV add‐on therapy may be necessary to reduce the incidence of developing ADV resistance in patients with LAM resistance.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>19196395</pmid><doi>10.1111/j.1440-1746.2008.05570.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2009-01, Vol.24 (1), p.49-54 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66891079 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | adefovir Adenine - analogs & derivatives Adenine - therapeutic use Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use antiviral resistance Biological and medical sciences DNA, Viral - blood Drug Resistance, Multiple, Viral - genetics Female Gastroenterology. Liver. Pancreas. Abdomen Hepatitis B - diagnosis Hepatitis B - drug therapy Hepatitis B virus Hepatitis B virus - genetics Humans Lamivudine - therapeutic use Male Medical sciences Middle Aged Mutation Organophosphonates - therapeutic use Pharmacology. Drug treatments Polymorphism, Restriction Fragment Length Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Time Factors Treatment Outcome Viral Load YMDD mutants |
| title | Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A56%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emergence%20of%20adefovir-resistant%20mutants%20after%20reversion%20to%20YMDD%20wild-type%20in%20lamivudine-resistant%20patients%20receiving%20adefovir%20monotherapy&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Kwon,%20Hyeok%20Choon&rft.date=2009-01&rft.volume=24&rft.issue=1&rft.spage=49&rft.epage=54&rft.pages=49-54&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/j.1440-1746.2008.05570.x&rft_dat=%3Cproquest_cross%3E66891079%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20347804&rft_id=info:pmid/19196395&rfr_iscdi=true |